Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG.
In a randomized, double-blind, placebo-controlled study in 64 subjects with Huntington disease (HD), 8 g/day of creatine administered for 16 weeks was well tolerated and safe. Serum and brain creatine concentrations increased in the creatine-treated group and returned to baseline after washout. Serum 8-hydroxy-2'-deoxyguanosine (8OH2'dG) levels, an indicator of oxidative injury to DNA, were markedly elevated in HD and reduced by creatine treatment.
Hersch
S M
SM
Department of Neurology, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA. hersch@helix.mgh.harvard.edu
Gevorkian
S
S
Marder
K
K
Moskowitz
C
C
Feigin
A
A
Cox
M
M
Como
P
P
Zimmerman
C
C
Lin
M
M
Zhang
L
L
Ulug
A M
AM
Beal
M F
MF
Matson
W
W
Bogdanov
M
M
Ebbel
E
E
Zaleta
A
A
Kaneko
Y
Y
Jenkins
B
B
Hevelone
N
N
Zhang
H
H
Yu
H
H
Schoenfeld
D
D
Ferrante
R
R
Rosas
H D
HD
D000080242:8-Hydroxy-2'-Deoxyguanosine; D000328:Adult; D001682:Biological Availability; D015415:Biomarkers / Q000378:metabolism; D001921:Brain / Q000378:metabolism*; D003401:Creatine / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D003849:Deoxyguanosine / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors / Q000097:blood; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006816:Huntington Disease / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism*; D008297:Male; D008875:Middle Aged
D015415:Biomarkers; D000080242:8-Hydroxy-2'-Deoxyguanosine; D003849:Deoxyguanosine; D003401:Creatine